Drugs / Orilissa
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ORILISSA | — | 2021-02-01 | fda.gov ↗ |
| Approved | US (FDA) | ORILISSA | — | 2018-07-23 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06253702 Background | Jul 2024 → May 2025 | cerebrovascular disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Orilissa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06253702 ↗ |